Aller au contenu principal
Profil bibliographique

Jillian M. Adams

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

5Publications signalées
16Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

Phagocytosis and Immune RegulationHead and Neck Cancer StudiesFatigue and fracture mechanicsLung Cancer Treatments and MutationsImmune cells in cancer

Les publications récentes

Accès ouvert 2025 article OpenAlex

Tumor-associated MerTK promotes a pro-inflammatory microenvironment and enhances immune checkpoint inhibitor response in triple-negative breast cancer

Bridget E. Crossman, Regan L. Harmon, Mari Iida, Jillian M. Adams et autres

Introduction: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with no targeted treatment modalities. Currently, combination chemotherapy and immune checkpoint inhibitor (ICI) therapy are options for many TNBC patients; however, their efficacy is limited. Understanding what makes TNBCs responsive …

us (code pays fourni par la source)

0 citations Frontiers in Oncology
Accès ouvert 2024 article OpenAlex

From Bench to Bedside: A Team’s Approach to Multidisciplinary Strategies to Combat Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma

Bridget E. Crossman, Regan L. Harmon, Kourtney L. Kostecki, Nellie K. McDaniel et autres

Head and neck squamous cell carcinoma (HNSCC) is diagnosed in more than 71,000 patients each year in the United States, with nearly 16,000 associated deaths. One significant hurdle in the treatment of HNSCC is acquired and intrinsic resistance to existing therapeutic agents. …

us (code pays fourni par la source)

7 citations Journal of Clinical Medicine
Accès ouvert 2024 article OpenAlex

MerTK Drives Proliferation and Metastatic Potential in Triple-Negative Breast Cancer

Mari Iida, Bridget E. Crossman, Kourtney L. Kostecki, Christine E. Glitchev et autres

Triple-negative breast cancer (TNBC) is characterized by the absence of the estrogen receptor, progesterone receptor, and receptor tyrosine kinase HER2 expression. Due to the limited number of FDA-approved targeted therapies for TNBC, there is an ongoing need to understand the molecular underpinnings …

us (code pays fourni par la source)

8 citations International Journal of Molecular Sciences
2024 conference-abstract OpenAlex

Abstract 6994: MerTK drives proliferation and metastasis activity in triple negative breast cancer

Christine E. Glitchev, Mari Iida, Bridget E. Crossman, Kourtney L. Kostecki et autres

Abstract Triple negative breast cancer (TNBC) is characterized by the absence of estrogen, progesterone, and HER2 receptors. It exhibits a higher level of aggressiveness compared to other types of breast cancer, with a greater likelihood of recurrence following standard treatments such as …

us (code pays fourni par la source)

0 citations Cancer Research

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.